×
About 12,315 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  4,273 results

Gene mutational profile of BRCAness and clinical implication in predicting response to ...
https://doi.org/10.1016/j.ejca.2022.05.004
European Journal of Cancer (Oxford, England : 1990); Rimini M, Macarulla T et. al.

Jun 25th, 2022 - Biliary tract cancers are rare malignancies with a poor prognosis and scarce therapeutic strategies. The significance of BRCAness in this setting is already unknown. Tissue specimens of BTC patients treated with platinum-based chemotherapy have be...

Recurrent bacteremia with a hypermucoviscous Escherichia coli isolated from a patient w...
https://doi.org/10.1186/s12941-022-00521-7 10.1111/jam.13468 10.3389/fcimb.2015.00023 10.1111/1469-0691.12646 10.1128/JCM.00816-08 10.1016/bs.ampbs.2014.08.006 10.1128/iai.61.8.3164-3174.1993 10.3389/fmicb.2018.02026 10.1016/j.clinmicnews.2010.05.001 10.4161/viru.22718 10.1093/qjmed/hcu124 10.1038/s41467-018-05114-7 10.1111/joim.13007 10.3390/microorganisms9010133 10.1080/21505594.2017.1317412 10.1186/s13046-019-1515-2 10.1186/1471-2334-10-307 10.1210/jc.2005-2749 10.3390/nu13031018 10.1007/s10096-016-2669-x 10.3748/wjg.v26.i14.1638 10.1016/j.jinf.2013.04.008 10.1186/s13099-021-00429-1 10.1086/343828 10.1158/1055-9965.EPI-20-0705 10.12659/MSM.914987 10.31557/APJCP.2021.22.1.233 10.1186/s13099-020-00375-4 10.1006/abio.1995.1220 10.1093/jac/dkab407 10.1371/journal.pcbi.1005595 10.1093/nar/gkw569 10.1038/nbt.2522 10.1093/jac/dkaa345 10.1128/JCM.01269-20 10.1093/jac/dkaa390 10.1101/gr.251678.119 10.1038/s41467-021-24448-3 10.1093/nar/gkab1111 10.1093/bioinformatics/btn322 10.1093/nar/gkn179 10.1101/gr.809403 10.1371/journal.ppat.1009376 10.3389/fmicb.2021.786146 10.1371/journal.pone.0074423 10.1128/AEM.01661-19 10.1016/j.resmic.2005.03.006 10.1016/j.tvjl.2006.05.019 10.1186/s13099-018-0271-8 10.1128/CMR.00135-18 10.1093/jac/dkaa161 10.1111/1758-2229.12710 10.3389/fmicb.2021.642484 10.1099/mgen.0.000196 10.1093/nar/gkw387 10.1093/bib/bbx121 10.1128/AAC.43.4.868 10.1128/AAC.00602-16 10.1128/AAC.00665-15 10.1128/IAI.01333-08 10.1074/jbc.M412885200 10.3389/fcimb.2021.688989 10.3389/fmed.2017.00163 10.1371/journal.pone.0057794
Annals of Clinical Microbiology and Antimicrobials; Neumann B, Lippmann N et. al.

Jun 25th, 2022 - Escherichia coli (E. coli) is a common human pathogen, responsible for a broad spectrum of infections. Sites of infection can vary, but the hepato-biliary system is of particular concern due to the infection-associated formation of gallstones and ...

Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients ...
https://clinicaltrials.gov/ct2/show/NCT04431024

Jun 24th, 2022 - Background: Mutations involving BRCA1-Associated Protein-1 (BAP1), a nuclear deubiquitinase involved in epigenetic regulation of gene expression, DNA repair, and cellular energetics, have emerged as one of the most common somatic mutations in mali...

Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04645160

Jun 24th, 2022 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-...

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03412877

Jun 24th, 2022 - Background: The administration of autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of participants with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique...

see more →

Guidelines  9 results

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice G...
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd ...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 24th, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  429 results

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT04145141

Jun 24th, 2022 - Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancer with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellul...

Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients ...
https://clinicaltrials.gov/ct2/show/NCT04431024

Jun 24th, 2022 - Background: Mutations involving BRCA1-Associated Protein-1 (BAP1), a nuclear deubiquitinase involved in epigenetic regulation of gene expression, DNA repair, and cellular energetics, have emerged as one of the most common somatic mutations in mali...

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03412877

Jun 24th, 2022 - Background: The administration of autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of participants with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique...

Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04645160

Jun 24th, 2022 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

Jun 24th, 2022 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intr...

see more →

News  205 results

Patient Factors Linked With Liver Remnant Growth in Staged Hepatectomy
https://www.medscape.com/viewarticle/975730

Jun 17th, 2022 - NEW YORK (Reuters Health) - In patients undergoing staged hepatectomy for liver tumors, a technique that combines portal vein ligation and parenchymal in situ split allows for rapid, enhanced hypertrophy of the future liver remnant, and now resear...

What Is the Optimal Treatment for Multifocal Intrahepatic Cholangiocarcinoma?
https://www.medscape.com/viewarticle/974146

May 18th, 2022 - NEW YORK (Reuters Health) - In patients with multifocal intrahepatic cholangiocarcinoma (iCCA), hepatic arterial infusion pump (HAIP) floxuridine chemotherapy may be an effective alternative to surgery, a cohort study suggests. "We believe that th...

European Approval Sought for Ivosidenib in IDH1-Mutated AML and Cholangiocarcinoma
https://www.onclive.com/view/european-approval-sought-for-ivosidenib-in-idh1-mutated-aml-and-cholangiocarcinoma

Apr 22nd, 2022 - A marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for 2 indications of ivosidenib (Tibsovo): in combination with azacitidine in the frontline treatment of patients with IDH1-mutated acute myeloid...

KIN-3248 Under Exploration in Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Alterations
https://www.onclive.com/view/kin-3248-under-exploration-in-advanced-solid-tumors-harboring-fgfr2-and-or-fgfr3-alterations

Apr 21st, 2022 - The safety, tolerability, and preliminary efficacy of the irreversible, small molecule pan-FGFR inhibitor KIN-3248 is under investigation in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, as part of the phase 1 ...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

see more →

Patient Education  7 results see all →